David Aaron Lehman Sells 14,334 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) General Counsel David Lehman sold 14,334 shares of Pulmonx stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $32,394.84. Following the completion of the sale, the general counsel owned 361,827 shares of the company’s stock, valued at approximately $817,729.02. The trade was a 3.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Price Performance

Shares of LUNG opened at $2.21 on Friday. The firm has a market cap of $94.92 million, a PE ratio of -1.91 and a beta of 0.34. Pulmonx Corporation has a 52-week low of $1.13 and a 52-week high of $2.89. The business’s 50 day moving average price is $1.82 and its two-hundred day moving average price is $1.57. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. The company had revenue of $22.76 million during the quarter, compared to the consensus estimate of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. On average, equities analysts anticipate that Pulmonx Corporation will post -1.05 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on LUNG. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings raised shares of Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 25th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $7.67.

Hedge Funds Weigh In On Pulmonx

A number of institutional investors have recently modified their holdings of LUNG. Primecap Management Co. CA acquired a new stake in Pulmonx in the 2nd quarter valued at $5,996,000. ExodusPoint Capital Management LP acquired a new position in Pulmonx during the fourth quarter worth $4,312,000. Almitas Capital LLC acquired a new position in Pulmonx during the second quarter worth $1,383,000. BlackRock Inc. bought a new position in shares of Pulmonx in the second quarter valued at $1,147,000. Finally, Vestal Point Capital LP bought a new position in shares of Pulmonx in the third quarter valued at $1,345,000. 91.04% of the stock is owned by institutional investors and hedge funds.

Key Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Analyst sentiment remains broadly favorable, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus. The average price target of $7.67 is substantially above recent trading levels, suggesting significant potential upside if Pulmonx delivers on its growth plans. Pulmonx analyst and earnings information
• Positive Sentiment: Pulmonx’s latest quarterly results exceeded expectations: revenue was $22.76 million versus the $22.39 million consensus estimate, while its loss of $0.24 per share was narrower than the expected $0.28 loss. Pulmonx quarterly results
• Neutral Sentiment: CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan sold a combined 78,340 shares at approximately $2.26 per share. The filings say the transactions covered tax-withholding obligations related to vested equity awards, reducing their significance as a signal of declining confidence; however, the sales may add modest short-term supply. Pulmonx insider sales report
• Negative Sentiment: Recent gains have triggered profit-taking, contributing to the stock’s retreat and weakening short-term trading sentiment. Pulmonx shares fall following recent gains
• Negative Sentiment: Pulmonx remains unprofitable, and analysts expect a full-year loss of roughly $1.05 per share. The company’s negative margins and uncertain path to sustained profitability are keeping investors cautious despite the earnings beat. Pulmonx profit-taking and earnings outlook

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.